Biofrontera (BFRI) EBIT Margin (2020 - 2025)
Historic EBIT Margin for Biofrontera (BFRI) over the last 6 years, with Q3 2025 value amounting to 89.84%.
- Biofrontera's EBIT Margin fell 348000.0% to 89.84% in Q3 2025 from the same period last year, while for Sep 2025 it was 47.4%, marking a year-over-year increase of 73600.0%. This contributed to the annual value of 46.11% for FY2024, which is 204400.0% up from last year.
- According to the latest figures from Q3 2025, Biofrontera's EBIT Margin is 89.84%, which was down 348000.0% from 56.25% recorded in Q2 2025.
- In the past 5 years, Biofrontera's EBIT Margin registered a high of 13.63% during Q4 2024, and its lowest value of 371.6% during Q3 2021.
- Over the past 5 years, Biofrontera's median EBIT Margin value was 62.89% (recorded in 2023), while the average stood at 81.13%.
- In the last 5 years, Biofrontera's EBIT Margin crashed by -2995200bps in 2021 and then soared by 2874000bps in 2022.
- Over the past 5 years, Biofrontera's EBIT Margin (Quarter) stood at 20.51% in 2021, then plummeted by -168bps to 55.02% in 2022, then surged by 34bps to 36.48% in 2023, then soared by 63bps to 13.63% in 2024, then plummeted by -559bps to 89.84% in 2025.
- Its EBIT Margin stands at 89.84% for Q3 2025, versus 56.25% for Q2 2025 and 52.95% for Q1 2025.